ASCO 2026 Highlights: What Emerging Therapies and Shifting Standards Reveal About the Future of Cancer Care
- Kiara Wassoodew
- 4 minutes ago
- 7 min read
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting underscored how advances in cancer care are reshaping the oncology landscape. The meeting—one of the world's largest and most influential oncology conferences—attracted more than 44,000 attendees from over 160 countries, serving as a forum to shape a shared vision for the future of cancer care (1-3).
This year's meeting theme, "The Science and Practice of Translation: Improving Cancer Outcomes Worldwide," placed scientific breakthroughs and real-world application at the forefront, with a particular emphasis on global access and equity (2). The discussions made clear that oncology is at a meaningful inflection point—with targeted therapies reaching new disease areas, next-generation bispecific antibodies redefining immunotherapy, the expanding role of antibody-drug conjugates, and the push to translate scientific progress into global impact. The key highlights are explored below.
The discussions made clear that oncology is at a meaningful inflection point
Targeted Therapies in Novel Territories
This year's conference highlighted meaningful advances in cancer drug development, particularly around targeted therapies. One of the most anticipated sessions, the Plenary Session (4), showcased progress in developing targeted treatments for cancers driven by well-characterized mutations, where chemotherapy has historically remained the primary standard of care (5).
Targeted therapies are now reaching cancers long considered out of scope—a shift best illustrated by new data in KRAS-mutant pancreatic cancer. Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a cancer where KRAS mutations are common, yet targeted options have historically been unavailable (6). the RASolute 302 trial demonstrated that daraxonrasib, a pan-KRAS inhibitor, nearly doubled both overall survival and progression-free survival compared with standard chemotherapy, while producing fewer serious adverse events (7,8). If approved, daraxonrasib would mark a new standard of care for this patient population—and signal that even the most treatment-resistant, mutation-driven cancers are no longer beyond the reach of targeted therapy.
If approved, daraxonrasib would mark a new standard of care for this patient population—and signal that even the most treatment-resistant, mutation-driven cancers are no longer beyond the reach of targeted therapy.
Similar trends were seen in prostate cancer this year. In the PROTEUS trial, perioperative apalutamide plus androgen deprivation therapy reduced the risk of metastasis by 20% in high-risk localized disease (5). Patients were about 10 times more likely to have little or no residual cancer at the time of surgery compared with hormone therapy alone (9-11). These results reveal that treatment before and after surgery instead of only post-surgery could emerge as the new standard of care for high-risk prostate cancer.
Advancing Immunotherapy Through Bispecific Antibody Design
At this year's conference, bispecific antibodies (bsAbs) emerged as a notable area of focus. Unlike conventional monoclonal antibodies, bispecifics target two antigens simultaneously, and offer potential advantages in both efficacy and breadth of patients who benefit.
Bispecific antibodies are showing clear advantages over single-pathway inhibitors as demonstrated by new data in advanced squamous NSCLC. The HARMONi-6 trial evaluated ivonescimab, a first-in-class PD-1/VEGF bispecific antibody plus chemotherapy against the current standard of care i.e., tislelizumab and chemotherapy (12,13). Ivonescimab reduced the risk of death by 34% compared to tislelizumab, an established PD-1 inhibitor (12,13). The benefit held regardless of PD-L1 expression levels—a population that has historically seen limited benefit from checkpoint inhibitors alone (14). This effectively expands the eligible treatment population beyond those with high PD-L1 expression (12,13).
The same signal emerged with pumitamig, a PD-L1/VEGF-A bispecific antibody, in the ROSETTA Lung-02 trial (15). Pumitamig plus chemotherapy produced an overall response rate of 70% across both squamous and non-squamous NSCLC, with a disease control rate of 100%, regardless of PD-L1 expression (15,16). With Phase 3 now underway, the data adds to a growing body of evidence that dual-pathway targets can deliver meaningful responses in patients who might otherwise see limited benefit from immunotherapy alone.
The Expanding Role of Antibody-Drug Conjugates
Antibody-drug conjugates were among the most discussed drug classes at this year's conference, reflecting the significant momentum this platform has built in recent years. With several FDA approvals for ADCs coming in since 2020, the field has moved beyond proof of concept and into a more nuanced set of questions around payload optimization and ADC sequencing (17).
Triple-negative breast cancer was one area where those questions came into focus. TNBC remains one of the most challenging populations to treat, and data from ongoing studies evaluating Sacituzumab govitecan, a TROP2-directed ADC, underscored a dynamic the field is increasingly navigating. As multiple TROP2-directed ADCs become available for the same patient populations, clinical decision-making will hinge on carefully weighing efficacy and payload-related toxicity to determine ADC sequencing (18).
Broader discussions also centered on the potential of combining ADCs with immune checkpoint inhibitors. ICIs restore immune-mediated tumor recognition through T-cell activation, while ADCs deliver targeted cytotoxic cell death—two mechanisms that could produce more durable responses in combination than either achieves independently (19). These conversations are already shaping the design of next-generation Phase III trials, positioning combination treatments as the path forward for expanding treatment in refractory cancers (19).
Translating Scientific Progress into Global Impact at ASCO 2026
Running as an undercurrent throughout the week was a question that ASCO president Dr. Eric Small placed at the heart of this year's meeting: what does a scientific breakthrough mean if it doesn't reach the patients who need it most? As scientific progress continues and innovative therapies emerge, disparities in global cancer outcomes continue to widen (20). Discussions were centered around accessible solutions, emphasizing that progress requires addressing concerns regarding affordability, ease of administration, and patient support outside of healthcare settings (20).
This held true in industry as well. Asian companies, whose therapies featured prominently at this year's meeting, are pursuing pricing and manufacturing strategies designed to improve access in emerging markets (21). Notably, many are also tailoring treatments to the cancer profiles most prevalent in their regions—a meaningful consideration given that Asia carries a disproportionate share of the cancer burden (21). This is increasingly paired with stronger local research infrastructure, which is bringing historically underrepresented populations into clinical trials and beginning to address longstanding gaps in global trial diversity (21). Meanwhile, ASCO continues to work toward expanding oncology training, broadening access to clinical trials, and offering practical guidance for delivering equitable care (22).
This is increasingly paired with stronger local research infrastructure, which is bringing historically underrepresented populations into clinical trials and beginning to address longstanding gaps in global trial diversity (21).
The View from the Crow’s Nest
ASCO 2026 made clear that oncology is at an inflection point—one shaped as much by a shift in expectations as by the pace of scientific progress. Targeted therapies are reaching disease areas long considered out of scope, next-generation antibody platforms are redefining what immunotherapy can achieve, and combination strategies are emerging as the framework for the next wave of drug development. Running through all of it was a heightened sense of responsibility: that breakthrough science must be paired with an equal commitment to access and affordability. The conversations that defined this year's meeting will shape the trials, treatment pathways, and standards of care for years to come.
If you are interested in learning more, get in touch at strategy@spinnakerLS.com.
Spinnaker offers true partnership and comprehensive guidance to help leaders navigate the complexities of the Life Sciences industry and chart a path to success. From early-stage market assessment through commercial execution and ongoing lifecycle management, we deliver tailored solutions to ensure optimized practicable results.
References
1. AJMC. "Bring on the Breakthroughs: ASCO Takes Translation to More Patients." American Journal of Managed Care, 2026. https://www.ajmc.com/view/bring-on-the-breakthroughs-asco-takes-translation-to-more-patients
2. ASCO Connection. "2026 ASCO Annual Meeting: Join the Conversations That Will Improve Tomorrow's Outcomes." May 2026. https://connection.asco.org/do/2026-asco-annual-meeting-join-conversations-improve-tomorrow-s-outcomes
3. American Society of Clinical Oncology. "ASCO Annual Meeting." ASCO.org. https://www.asco.org/annual-meeting
4. American Society of Clinical Oncology. "Program Overview — 2026 ASCO Annual Meeting." ASCO.org, 2026. https://www.asco.org/annual-meeting/program/program-overview
5. Targeted Oncology. "2026 ASCO Plenary Delivers Practice-Changing Progress." Targeted Oncology, 2026. https://www.targetedonc.com/view/2026-asco-plenary-delivers-practice-changing-progress
6. BioPharma Dive. "ASCO '26: Bispecifics vs. ADCs, a 'RAS' Revolution and a Step Change in Prostate Cancer." June 2026. https://www.biopharmadive.com/news/asco-2026-daraxonrasib-ivonescimab-proteus-erleada-results/821622/
7. ASCO Press Center. "Multi-Selective RAS(ON) Inhibitor Nearly Doubles Survival Time in People With Metastatic Pancreatic Cancer." June 2026. https://www.asco.org/about-asco/press-center/multi-selective-ras-inhibitor-nearly-doubles-survival-pancreatic-cancer
8. The ASCO Post. "Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer." June 2026. https://ascopost.com/news/june-2026/daraxonrasib-nearly-doubles-survival-in-previously-treated-metastatic-pancreatic-cancer/
9. American Society of Clinical Oncology. “Potential New Targeted Treatment Option for People With Localized High-Risk Prostate Cancer.” ASCO Press Center, May 31, 2026. https://www.asco.org/about-asco/press-center/potential-new-targeted-treatment-localized-high-risk-prostate
10. The ASCO Post. “PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer.” June 2026. https://ascopost.com/news/june-2026/proteus-trial-suggests-perioperative-apalutamide-may-improve-outcomes-in-high-risk-localized-prostate-cancer/
11. Taplin ME, et al. “Perioperative Apalutamide in High-Risk Localized Prostate Cancer.” New England Journal of Medicine, 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa2603878
12. The ASCO Post. “Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC.” June 2026. https://ascopost.com/news/june-2026/overall-survival-benefit-with-ivonescimab-plus-chemotherapy-in-advanced-squamous-nsclc/
13. Akeso, Inc. / PRNewswire. “HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66).” May 2026. https://www.prnewswire.com/news-releases/harmoni-6-demonstrates-significant-overall-survival-benefit-hr0-66-ivonescimab-plus-chemotherapy-superior-to-pd-1-plus-chemotherapy-in-first-line-sq-nsclc-landmark-results-to-be-presented-at-asco-2026-plenary-session-302786433.html
14. Twomey JD, Zhang B. “Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.” The AAPS Journal 23, no. 39 (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC7937597/
15. American Society of Clinical Oncology. “Phase 2 Data from ROSETTA Lung-02, a Global Randomized Phase 2/3 Trial of Pumitamig (PD-L1 x VEGF-A bsAb) + Chemotherapy in 1L NSCLC.” ASCO 2026 Abstract. https://www.asco.org/abstracts-presentations/261380
16. Bristol Myers Squibb / BioNTech. “Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial.” Press Release, May 30, 2026. https://news.bms.com/news/corporate-financial/2026/Global-Data-for-BioNTech-and-Bristol-Myers-Squibbs-PD-L1xVEGF-A-Bispecific-Pumitamig-Shows-Encouraging-Efficacy-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-ROSETTA-Lung-02-Trial-2026-TW53rMYYjx/default.aspx
17. Tarantino P, et al. “Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens.” PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12737156/
18. Medscape. “ASCO 2026: Previewing Updates on ADCs and SERDs in Metastatic Breast Cancer.” 2026. https://www.medscape.com/viewarticle/mdangle-asco-2026-metastatic-breast-cancer-preview-2026a1000cks
19. Lu Y, et al. “Reprogramming the Tumor Microenvironment: Synergistic Mechanisms of Antibody–Drug Conjugates and Immune Checkpoint Inhibitors.” Antibody Therapeutics, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12451267/
20. GeneOnline News. “Navigating the Translational Future of Cancer Care with ASCO 2026 Late-Breaking Abstracts.” June 2026. https://www.geneonline.com/navigating-the-translational-future-of-cancer-care-with-asco-2026-late-breaking-abstracts/
21. BioSpectrum Asia. “ASCO 2026 Marked a Defining Moment for Asian Oncology Innovation.” June 2026. https://www.biospectrumasia.com/analysis/41/27713/asco-2026-marked-a-defining-moment-for-asian-oncology-innovation.html
22. OncoDaily. “ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact.” 2025. https://oncodaily.com/insight/asco-2026-presidential-theme-eric-small